Onconova Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative small molecule drug candidates for the treatment of cancer. With a focus on targeted anti-cancer agents, Onconova aims to disrupt specific cellular pathways that are critical for cancer cell proliferation. One of their promising products is the multi-kinase inhibitor narazaciclib (ON 123300), which is currently being evaluated in Phase 1 dose-escalation and expansion studies in the United States and China.

Additionally, Onconova is conducting a Phase 1/2a investigator-initiated study on their product candidate oral rigosertib, which targets patients with advanced KRAS+ lung adenocarcinoma in combination with nivolumab. Established in 1998, Onconova Therapeutics has a strong mission to provide novel solutions to cancer patients, improving outcomes and reducing the burden of side effects associated with current treatment methods. Led by a management team with extensive expertise in targeted cancer therapeutics, clinical development, and commercialization, Onconova Therapeutics is committed to making a difference in the field of oncology